ATRX and central nervous system cancer: For example, five-year survival of patients with gliomas containing IDH mutation or ATRX mutation (IDH and ATRX are mutually exclusive) and 1p/19q co-deletion is up to 80%, whereas those with gliomas not containing IDH or ATRX mutation and without 1p/19q codeletion is 5% [22].